{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:44:52Z","timestamp":1790815492016,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.vaccine.2022.04.079","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T22:23:48Z","timestamp":1652307828000},"page":"3546-3555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Persistence of antibodies, boostability, and interchangeability of Japanese encephalitis vaccines: A systematic review and dose-response meta-analysis"],"prefix":"10.1016","volume":"40","author":[{"given":"Nazmul","family":"Islam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen L.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor J.","family":"Devine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon E.","family":"Hugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayan","family":"Gyawali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukman","family":"Thalib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Furuya-Kanamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.vaccine.2022.04.079_b0005","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.medmal.2011.05.015","article-title":"Epidemiology of viral encephalitis in 2011","volume":"41","author":"Stahl","year":"2011","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.vaccine.2022.04.079_b0010","unstructured":"SAGE Working Group on Japanese encephalitis vaccines. Background paper on Japanese encephalitis vaccines 2014. Available from: https:\/\/www.who.int\/immunization\/sage\/meetings\/2014\/october\/1_JE_Vaccine_Background_Paper.pdf. (Accessed online March 2022)."},{"key":"10.1016\/j.vaccine.2022.04.079_b0015","doi-asserted-by":"crossref","first-page":"e51027","DOI":"10.7554\/eLife.51027","article-title":"Estimates of the global burden of Japanese encephalitis and the impact of vaccination from 2000\u20132015","volume":"9","author":"Quan","year":"2020","journal-title":"Elife"},{"issue":"9494","key":"10.1016\/j.vaccine.2022.04.079_b0020","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(05)67567-8","article-title":"Effect of single dose of SA 14\u201314-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study","volume":"366","author":"Ohrr","year":"2005","journal-title":"Lancet"},{"issue":"9284","key":"10.1016\/j.vaccine.2022.04.079_b0025","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0140-6736(01)05967-0","article-title":"Efficacy of single-dose SA 14\u201314-2 vaccine against Japanese encephalitis: a case control study","volume":"358","author":"Bista","year":"2001","journal-title":"Lancet"},{"issue":"9015","key":"10.1016\/j.vaccine.2022.04.079_b0030","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/S0140-6736(96)91075-2","article-title":"Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study","volume":"347","author":"Hennessy","year":"1996","journal-title":"Lancet"},{"issue":"32","key":"10.1016\/j.vaccine.2022.04.079_b0035","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1016\/j.vaccine.2021.06.023","article-title":"Comparison of immunogenicity and safety of licensed Japanese encephalitis vaccines: A systematic review and network meta-analysis","volume":"39","author":"Furuya-Kanamori","year":"2021","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2022.04.079_b0040","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.vaccine.2009.10.024","article-title":"Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age","volume":"28","author":"Kaltenb\u00f6ck","year":"2010","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2022.04.079_b0045","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.vaccine.2008.02.042","article-title":"Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14\u201314-2 vaccine in Philippine infants","volume":"26","author":"Gatchalian","year":"2008","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2022.04.079_b0050","doi-asserted-by":"crossref","first-page":"929","DOI":"10.4161\/hv.20071","article-title":"Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12\u201318 months: randomized, controlled phase 3 immunogenicity and safety trial","volume":"8","author":"Feroldi","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"32","key":"10.1016\/j.vaccine.2022.04.079_b0055","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1016\/j.vaccine.2010.05.069","article-title":"Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51","volume":"28","author":"Dubischar-Kastner","year":"2010","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2022.04.079_b0060","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.vaccine.2008.12.062","article-title":"Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study","volume":"27","author":"Schuller","year":"2009","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2022.04.079_b0065","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.4161\/hv.6.12.13057","article-title":"Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults","volume":"6","author":"Nasveld","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2022.04.079_b0070","unstructured":"Australian Government - Department of Health. Japanese encephalitis 2018. Available from: https:\/\/immunisationhandbook.health.gov.au\/vaccine-preventable-diseases\/japanese-encephalitis (Accessed online March 2022)."},{"issue":"14","key":"10.1016\/j.vaccine.2022.04.079_b0075","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/j.vaccine.2011.01.058","article-title":"Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO\u00ae, IC51","volume":"29","author":"Eder","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.04.079_b0080","doi-asserted-by":"crossref","unstructured":"Feroldi E, Capeding MR, Boaz M, Gailhardou S, Meric C, Bouckenooghe A. Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children. Hum Vaccin Immunother. 2013;9(4):889-97. Epub 2013\/02\/28. doi: 10.4161\/hv.23087.","DOI":"10.4161\/hv.23087"},{"key":"10.1016\/j.vaccine.2022.04.079_b0085","unstructured":"World Health O. Japanese Encephalitis Vaccines = Vaccins contre l\u2019enc\u00e9phalite japonaise. 2006. p. 331\u201340."},{"issue":"39","key":"10.1016\/j.vaccine.2022.04.079_b0090","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1016\/j.vaccine.2010.07.040","article-title":"Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO (IC51), in 6 months of follow-up","volume":"28","author":"Dubischar-Kastner","year":"2010","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2022.04.079_b0095","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.079_b0100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.5195\/jmla.2020.834","article-title":"Improving the translation of search strategies using the Polyglot Search Translator: a randomized controlled trial","volume":"108","author":"Clark","year":"2020","journal-title":"J Med Libr Assoc"},{"key":"10.1016\/j.vaccine.2022.04.079_b0105","series-title":"Chapter 3: Systematic reviews of effectiveness","author":"Tufanaru","year":"2017"},{"issue":"3","key":"10.1016\/j.vaccine.2022.04.079_b0110","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/XEB.0000000000000132","article-title":"The robust error meta-regression method for dose\u2013response meta-analysis","volume":"1","author":"Xu","year":"2018","journal-title":"Int J Evid Based Healthc"},{"issue":"Pt A","key":"10.1016\/j.vaccine.2022.04.079_b0115","first-page":"130-8","article-title":"Advances in the meta-analysis of heterogeneous clinical trials I: The inverse heterogeneity model","volume":"45","author":"Doi","year":"2015","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.vaccine.2022.04.079_b0120","series-title":"Statistical Software Components S458793","article-title":"REMR: Stata module to implement robust error meta-regression method for dose\u2013response meta-analysis","author":"Furuya-Kanamori","year":"2020"},{"key":"10.1016\/j.vaccine.2022.04.079_b0125","unstructured":"Fisher D, Harris R, Bradburn M, Deeks J, Harbord R, Altman D, et al. METAN: Stata module for fixed and random effects meta-analysis. 2021. Statistical Software Components S456798, Boston College Department of Economics."},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.079_b0130","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/21645515.2015.1011996","article-title":"Comparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: A systematic review and meta-analysis","volume":"11","author":"Wang","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"10.1016\/j.vaccine.2022.04.079_b0135","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.4161\/21645515.2014.980197","article-title":"Immunogenicity and safety of currently available Japanese encephalitis vaccines: a systematic review","volume":"10","author":"Li","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.079_b0140","doi-asserted-by":"crossref","first-page":"taaa016","DOI":"10.1093\/jtm\/taaa016","article-title":"Vaccination against Japanese encephalitis with IC51: systematic review on immunogenicity, duration of protection and safety","volume":"27","author":"Kling","year":"2020","journal-title":"J Travel Med"},{"issue":"30","key":"10.1016\/j.vaccine.2022.04.079_b0145","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1016\/j.vaccine.2015.05.037","article-title":"Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis","volume":"33","author":"Paulke-Korinek","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.079_b0150","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/21645515.2018.1515455","article-title":"Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine","volume":"15","author":"Bouckenooghe","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"15","key":"10.1016\/j.vaccine.2022.04.079_b0155","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1016\/j.vaccine.2012.02.005","article-title":"Modelling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine","volume":"30","author":"Desai","year":"2012","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2022.04.079_b0160","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/378356","article-title":"Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen","volume":"188","author":"Monath","year":"2003","journal-title":"J Infect Dis"},{"issue":"44","key":"10.1016\/j.vaccine.2022.04.079_b0165","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.1016\/j.vaccine.2016.09.005","article-title":"Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children","volume":"34","author":"Janewongwirot","year":"2016","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.079_b0170","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/INF.0000000000001395","article-title":"Immunogenicity of a live attenuated chimeric Japanese encephalitis vaccine as a booster dose after primary vaccination with live attenuated SA14-14-2 vaccine: a phase IV study in Thai children","volume":"36","author":"Sricharoenchai","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2022.04.079_b0175","doi-asserted-by":"crossref","unstructured":"Rathore APS, St John AL. Cross-reactive immunity among flaviviruses. Front Immunol. 2020;11:334.","DOI":"10.3389\/fimmu.2020.00334"},{"issue":"32","key":"10.1016\/j.vaccine.2022.04.079_b0180","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1016\/j.vaccine.2020.05.054","article-title":"Immunogenicity and safety of two-visit, intradermal pre-exposure rabies prophylaxis simultaneously administrated with chimeric live-attenuated Japanese encephalitis vaccine in children living in rabies and Japanese encephalitis endemic country","volume":"38","author":"Angsuwatcharakon","year":"2020","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2022.04.079_b0185","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/infdis\/jix601","article-title":"Five-year antibody persistence following a Japanese encephalitis chimeric virus vaccine (JE-CV) booster in JE-CV\u2013primed children in the Philippines","volume":"217","author":"Capeding","year":"2018","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.04.079_b0190","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1080\/21645515.2017.1414763","article-title":"Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children","volume":"14","author":"Chanthavanich","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2022.04.079_b0195","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/tropej\/fmt043","article-title":"Is a booster dose necessary in children after immunization with live attenuated Japanese encephalitis vaccine?","volume":"59","author":"Choi","year":"2013","journal-title":"J Trop Pediatr"},{"issue":"46","key":"10.1016\/j.vaccine.2022.04.079_b0200","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1016\/j.vaccine.2016.09.018","article-title":"Long-term follow-up of Japanese encephalitis chimeric virus vaccine: immune responses in children","volume":"34","author":"Chokephaibulkit","year":"2016","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2022.04.079_b0205","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/INF.0b013e3181f68e9c","article-title":"Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2-to 5-year-olds and naive 12-to 24-month-olds: multicenter randomized controlled trial","volume":"29","author":"Chokephaibulkit","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.079_b0210","first-page":"221","article-title":"Persistence of wild-type Japanese encephalitis virus strains cross-neutralization 5 years after JE-CV immunization","volume":"215","author":"Feroldi","year":"2017","journal-title":"J Infect Dis"},{"issue":"32","key":"10.1016\/j.vaccine.2022.04.079_b0215","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1016\/j.vaccine.2010.05.069","article-title":"Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO\u00ae, IC51","volume":"28","author":"Dubischar-Kastner","year":"2010","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.079_b0220","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/cid\/cis542","article-title":"A single dose of Vero cell\u2013derived Japanese encephalitis (JE) vaccine (Ixiaro) effectively boosts immunity in travelers primed with mouse brain\u2013derived JE vaccines","volume":"55","author":"Erra","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.079_b0225","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.vaccine.2013.10.055","article-title":"Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study","volume":"32","author":"Erra","year":"2013","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2022.04.079_b0230","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1097\/INF.0000000000002124","article-title":"Antibody persistence up to 3 years after primary immunization with inactivated Japanese encephalitis vaccine IXIARO in Philippine children and effect of a booster dose","volume":"37","author":"Kadlecek","year":"2018","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.079_b0235","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1097\/INF.0000000000000967","article-title":"Immunogenicity and safety of a booster dose of a live attenuated Japanese encephalitis chimeric vaccine given 1 year after primary immunization in healthy children in the Republic of Korea","volume":"35","author":"Kim","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2022.04.079_b0240","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1097\/INF.0000000000001494","article-title":"Long-term immunogenicity of a single dose of Japanese encephalitis chimeric virus vaccine in toddlers and booster response 5 years after primary immunization","volume":"36","author":"Kosalaraksa","year":"2017","journal-title":"Pediatr Infect Dis J"},{"issue":"17","key":"10.1016\/j.vaccine.2022.04.079_b0245","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1016\/j.vaccine.2006.12.046","article-title":"A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis","volume":"25","author":"Lyons","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.04.079_b0250","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/infdis\/jiv023","article-title":"A Japanese encephalitis vaccine from India induces durable and cross-protective immunity against temporally and spatially wide-ranging global field strains","volume":"212","author":"Singh","year":"2015","journal-title":"J Infect Dis"},{"issue":"13","key":"10.1016\/j.vaccine.2022.04.079_b0255","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.vaccine.2008.01.021","article-title":"A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses","volume":"26","author":"Sohn","year":"2008","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.vaccine.2022.04.079_b0260","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.vaccine.2019.03.030","article-title":"Persistence of the immune response after vaccination with the Japanese encephalitis vaccine, IXIARO\u00ae in healthy adults: A five year follow-up study","volume":"37","author":"Taucher","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.04.079_b0265","doi-asserted-by":"crossref","first-page":"101616","DOI":"10.1016\/j.tmaid.2020.101616","article-title":"Neutralizing antibody persistence in pediatric travelers from non-JE-endemic countries following vaccination with IXIARO\u00ae Japanese encephalitis vaccine: An uncontrolled, open-label phase 3 follow-up study","volume":"34","author":"Taucher","year":"2020","journal-title":"Travel Med Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2022.04.079_b0270","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/infdis\/jiz672","article-title":"Persistence of immune responses with an inactivated Japanese encephalitis single-dose vaccine, JENVAC and interchangeability with a live-attenuated vaccine","volume":"222","author":"Vadrevu","year":"2020","journal-title":"J Infect Dis"},{"issue":"48","key":"10.1016\/j.vaccine.2022.04.079_b0275","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1016\/j.vaccine.2016.10.028","article-title":"Immunogenicity of live attenuated Japanese encephalitis SA 14\u201314-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine","volume":"34","author":"Wijesinghe","year":"2016","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2022.04.079_b0280","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1016\/j.vaccine.2012.02.063","article-title":"Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine","volume":"30","author":"Woolpert","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.079_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-014-0744-4","volume":"15","author":"Yun","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2022.04.079_b0290","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.vaccine.2018.01.075","volume":"36","author":"Yun","year":"2018","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:16:51Z","timestamp":1759403811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22005357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":58,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0264410X22005357"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.079","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistence of antibodies, boostability, and interchangeability of Japanese encephalitis vaccines: A systematic review and dose-response meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}